Carlos Curbelo Calls Out Jeff Sessions on Medical Marijuana
The Food and Drug Administration (FDA) signed off on allowing Canada-based company Tilray Inc. to import marijuana products for use in a clinical trial in the U.S. to test its effectiveness in treating essential tremor -- a nervous system (neurological) disorder that causes involuntary and rhythmic shaking. Congressman Carlos Curbelo (R-FL) immediately spotted the irony and is calling onAttorney General Jeff Sessions, who has vowed to use federal law to get tough on marijuana, to reverse course. “Allowing a Canadian company to do what American companies are still waiting on the Department of Justice to grant them permission to do is incomprehensible. The United States has countless companies, including several in my home state of Florida, that are well-equipped to provide high quality cannabis extracts, but they are being roadblocked by Attorney General Jeff Sessions’ senseless witch hunt against an entire industry of legal, state-regulated small businesses.” Currently, in the U.S., only the University of Mississippi is licensed to grow and harvest research-grade marijuana plants. More than 25 U.S.-based manufacturers have reportedly applied to the DEA to produce cannabis, but no action has been taken on those applications while Tilray was granted approval. “With this announcement, the Attorney General and the Department of Justice’s arcane prohibition on researching the effects of cannabis are now complicit in shipping American jobs and dollars abroad,” Curbelo said. This month, the House Judiciary Committee voted to move a bipartisan bill forward that would loosen the restrictions on sourcing medical cannabis for research. More here.